类风湿关节炎患者启动阿片类药物与大剂量非甾体抗炎药的心血管主要不良事件与死亡率比较
在FORWARD队列中,6866例启动阿片类药物的类风湿关节炎患者与13689例启动非甾体抗炎药的患者按倾向评分匹配后随访。阿片类药物组MACE风险与NSAIDs相似(HR=1.02,95%CI 0.85-1.22),但全因死亡率高33%(HR=1.33,95%CI 1.06-1.67),静脉血栓栓塞风险有升高趋势(HR=1.41,95%CI 0.84-2.35)。结论提示阿片类药物并不比NSAIDs更安全。
要点
- 阿片类药物组MACE风险与NSAIDs相似(HR=1.02,95%CI 0.85-1.22)。
- 阿片类药物组全因死亡率较NSAIDs高33%(HR=1.33,95%CI 1.06-1.67)。
- 强阿片类较弱阿片类相比NSAIDs的全因死亡和VTE风险更高,呈剂量依赖趋势。
核心结论
- 在类风湿关节炎患者中,阿片类药物与NSAIDs相比MACE风险相似,但全因死亡率升高且VTE可能升高,提示阿片类药物并不像临床医生所认为的那样比NSAIDs更安全。
研究设计与样本
- 在FORWARD(美国风湿病国家数据库)中开展的新使用者活性对照队列研究,纳入1998年至2021年间参与至少1年的类风湿关节炎患者。
- 每例阿片类药物启动者按倾向评分匹配2例NSAIDs启动者,随访至发生MACE复合终点(心肌梗死、卒中、心力衰竭、心血管病死亡、静脉血栓栓塞)和全因死亡。
- 采用Cox比例风险模型并校正倾向评分权重和不平衡协变量估计结局风险。
主要发现
- 6866例阿片类药物启动者与13689例NSAIDs启动者中,分别发生212例与253例MACE(20.6/1000人年 vs 18.9/1000人年)。
- 分别发生144例与150例死亡(13.5/1000人年 vs 10.8/1000人年)。
- 倾向评分加权模型中,阿片类药物组MACE风险与NSAIDs相似(HR=1.02,95%CI 0.85-1.22)。
- 倾向评分加权模型中,阿片类药物组全因死亡率较NSAIDs高33%(HR=1.33,95%CI 1.06-1.67)。
- MACE各组分中,阿片类药物启动者VTE风险倾向于高于NSAIDs启动者(HR=1.41,95%CI 0.84-2.35)。
关键数值与推荐
- 与NSAIDs相比,强阿片类较弱阿片类在全因死亡和VTE方面风险更高,提示剂量依赖关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Assess major adverse cardiovascular event (MACE) risk with opioids compared with non-steroidal anti-inflammatory drugs (NSAIDs) in patients with rheumatoid arthritis (RA) METHODS: We conducted a new-user active comparator cohort study among patients with RA within FORWARD, The National Databank for Rheumatic Diseases, with ≥1 year participation between 1998 and 2021. Each opioid initiator was matched to two NSAID initiators by propensity scores (PSs). Patients were followed until the occurrence of the composite endpoint of MACE (myocardial infarction, stroke, heart failure, cardiovascular disease (CVD) death, venous thromboembolism (VTE)) and all-cause mortality. The risk of outcomes was estimated using Cox proportional hazards with adjustment for PS weights and imbalanced covariables. RESULTS: Among 6866 opioid initiators and 13 689 NSAID initiators, 212 vs 253 MACE (20.6/1000 person-years (PY) vs 18.9/1000 PY) and 144 vs 150 deaths (13.5/1000 PY vs 10.8/1000 PY) occurred, respectively. The risk of MACE with opioids was similar to NSAIDs (HR=1.02, 95% CI 0.85 to 1.22), whereas all-cause mortality with opioids was 33% higher than NSAIDs (HR=1.33, 95% CI 1.06 to 1.67) in PS-weighted models. Among the individual outcomes of MACE, VTE risk tended to be higher in opioid initiators than NSAID initiators (HR=1.41, 95% CI 0.84 to 2.35). Strong opioids had a higher risk for all-cause mortality and VTE than weak opioids compared with NSAIDs suggesting a dose-dependent association. CONCLUSION: Opioids had similar MACE risk compared with NSAIDs in patients with RA with increased all-cause mortality and likely VTE, which suggests that opioids are not safer than NSAIDs, as clinicians have perceived.
引用
- Ozen G, Pedro S, Michaud K, et al. Major adverse cardiovascular events and mortality with opioids versus NSAIDs initiation in patients with rheumatoid arthritis. Ann Rheum Dis. 2023. PMID: 37460169. doi:10.1136/ard-2023-224339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。